Gilead Sciences, Inc. (GILD)

69.56
0.11 0.16
NASDAQ
Prev Close 69.67
Open 70.00
Day Low/High 69.31 / 70.46
52 Wk Low/High 56.56 / 73.34
Volume 7.73M
Exchange NASDAQ
Shares Outstanding 1254.38B
Market Cap 86.46B
P/E Ratio 68.31
Div & Yield N.A. (N.A)
Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

The Good, the Bad and the Ugly (3 p.m. Edition)

It's not a joke. It's a rope, Tuco. Now I want you to get up there and put your head in that noose. -- Blondie in "The Good, the Bad and the Ugly" I did no trading today, and there will be no "Takeaways" today. As expected, the markets have basicall...

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Don't Count on a Rally for Gilead

Don't Count on a Rally for Gilead

I would look for GILD to try to stabilize in the $70-$80 area before a more durable uptrend.

My Takeaways and Observations

At the end of the day!    Don't run with the crowd: Embrace contrary and second-level thinking instead.    Extreme policy uncertainty.    More Howard Marks.    Less Bill Miller.    My little sister!    Graf wrote a goodie.    The movie was in revers...

Credit Suisse Healthcare Conf.

Some Potential Positives Today

Some potential positives today: Strength in the Russell Index. Improving breadth. Improving Clinton odds by "538" and the London betting parlors. A great deal of pushback to my idea of a trading rally. Turnaround in large-cap biotech (Allergan , Cel...

What Makes for a Truly Great Stock?

What Makes for a Truly Great Stock?

This century's best-performing names offer some clues.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Health Care Sector Is Hurting

Cramer: Health Care Sector Is Hurting

You can't ignore the evidence.

My Takeaways and Observations

 A short "Takeaways" today as I have to prepare for some morning meetings.   Down, up, down -- in a relatively volatile session.   I am comfortable with yesterday's bearish moves.    I sold more (short) today on the surprising (at least to me!) ramp...

My Takeaways and Observations (Early Edition)

Don't get excited by Take Under Monday.   The technical picture is mixed.    A stronger U.S. dollar presents multi-national vulnerability. This is consistent with Goldman Sachs lowering their three-year S&P 500 profits picture.    Peak Sports Viewer...

Gilead Sciences Getting Some Analyst Love

It's nice to see some positive analyst commentary on Gilead Sciences this week. The biotech stalwart has had Buy ratings reiterated at three analyst firms in recent days. Also, earlier this week Gilead posted very positive results from trials around...

It's Not Easy Being Green: 3 Solid Names That Stand Out

It's Not Easy Being Green: 3 Solid Names That Stand Out

Look for solid companies showing life.

My Takeaways and Observations

The media is not the message. With a little help from Johnny Mercer, did you know he founded Capitol Records?   This is serious folks -- I see less of a reason to have an outsized long portfolio than at any time since Winter 2007. The market outlook...

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

On days like this, the money just keeps sloshing around.

These Dogs Are Becoming Cool Cats

These Dogs Are Becoming Cool Cats

The dreck of the first half will be the gems of year end.

My Takeaways and Observations

It was a nostalgic morning. A 20th anniversary.  My first TST column in 1997.  There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Gilead downgraded at Leerink

Cramer: Here Are the Reasons the Market Is Hated

Cramer: Here Are the Reasons the Market Is Hated

Apart from the Fed, there are other factors that make investors nervous.

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

You've Got the Brains, I've Got the Book, Let's Make Lots of Money

Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

3 Stocks That Could Still Rally

3 Stocks That Could Still Rally

It's been a nasty decline, but if we rally, these three have best charts.

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.

Citi Biotech Conf.

U.S. Stocks Gain Steam Despite Declines in Oil; GE Acquires 3D Printing Companies

U.S. Stocks Gain Steam Despite Declines in Oil; GE Acquires 3D Printing Companies

U.S. stocks rose Tuesday, as oil prices added one percent on hopes of a production freeze among the world's biggest oil producers.

Gilead upgraded at Jefferies

Gilead Sciences Could Be in For a Share Slump

Gilead Sciences Could Be in For a Share Slump

Gilead may be a value trap as investors grow frustrated after two years of stagnant growth.